Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Sapien 3 Performs Well in “Jobs” for Which It Is Not Designed

Using Sapien 3, transcatheter mitral valve replacement to treat failed bioprosthetic valves can be performed with a high degree of technical success.

Buen desempeño de la Sapien 3 en “trabajos” para los que no está diseñada

Failed mitral bioprosthetic valves are truly challenging due to how frequent symptoms are and the high morbidity/mortality associated with a new surgical replacement. Furthermore, there are no catheter options specifically designed to treat this issue.

Sapien 3 was developed as a last resource, but thanks to its good results, it is becoming a consistently good option.

Researchers analyzed prospectively all patients implanted with Sapien 3 to treat a failed mitral prosthesis between 2015 and 2019 included in the Society of Thoracic Surgeons (STS) registry. The primary efficacy endpoint was 1-year mortality, and secondary endpoints included 30-day mortality, New York Heart Association functional class, and valve performance.


Read also: Convalescent Plasma for Severe Pneumonia from COVID-19.


A total of 1529 patients were included; they had undergone a mitral valve-in-valve procedure through transseptal or transapical access in 295 sites. Technical success was achieved in 96.8% of patients and 30-day and 1-year mortality rates were 5.4% and 16.7%, respectively.

Transseptal access was linked to lower 1-year mortality compared with transapical access (15.8% vs. 21.7%; p = 0.03). 

New valve implantation provided immediate and sustained symptomatic relief. Baseline New York Heart Association functional class was III/IV in 87.1% of patients vs. 9.7% after a year.

Conclusion

Transcatheter mitral valve replacement in failed mitral bioprosthetic valves was associated with high technical success, lower 30-day/1-year mortality rates, and significant improvement of heart failure symptoms.

This option should be considered for most patients with failed mitral bioprosthetic valve and favorable anatomy.

Original Title: One-Year Outcomes of Mitral Valve-in-Valve Using the SAPIEN 3 Transcatheter Heart Valve.

Reference: Brian Whisenan et al. JAMA Cardiol. 2020;5(11):1245-1252. doi:10.1001/jamacardio.2020.2974.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

SCAI 2026 | Can an atrial fixation device prevent complications of transcatheter mitral valve replacement? Analysis of the AltaValve system

Transcatheter mitral valve replacement (TMVR) represents one of the most complex areas within structural interventions. Unlike TAVI, where valvular anatomy typically provides more predictable...

Beyond TAVI: Cardiac Rehabilitation as a Determinant of Clinical Outcomes

Aortic stenosis is an increasingly prevalent condition associated with population aging, with a prevalence of approximately 3.4% in individuals over 75 years of age...

Comparative outcomes between transaxillary approach and thoracotomy-based approaches in TAVI with alternative access

TAVI has become the standard treatment for high-risk aortic stenosis. When transfemoral access is not feasible (approximately 10–15%), alternative approaches are used: transaxillary (subclavian...

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

SCAI 2026 | Deep vein arterialization as an alternative in patients with critical limb ischemia without conventional options

Critical limb ischemia (CLI) represents one of the most advanced stages of peripheral arterial disease (PAD). In a significant proportion of patients, distal anatomy,...

SCAI 2026 | Can an atrial fixation device prevent complications of transcatheter mitral valve replacement? Analysis of the AltaValve system

Transcatheter mitral valve replacement (TMVR) represents one of the most complex areas within structural interventions. Unlike TAVI, where valvular anatomy typically provides more predictable...

SCAI 2026 | SELUTION DeNovo subanalysis: Use of sirolimus-eluting balloon in acute coronary syndrome

Percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation remains the predominant strategy in the setting of acute coronary syndrome (ACS). However, in recent...